{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T22:22:45Z","timestamp":1778106165291,"version":"3.51.4"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Therapeutic drug monitoring (TDM) is essential for voriconazole to ensure optimal drug exposure, mainly in critically ill patients for whom voriconazole demonstrated a large variability. The study aimed at describing factors associated with trough voriconazole concentrations in critically ill patients and evaluating the impact of voriconazole concentrations on adverse effects. A 2-year retrospective multicenter cohort study (NCT04502771) was conducted in six intensive care units. Adult patients who had at least one voriconazole TDM were included. Univariable and multivariable linear regression analyses were performed to identify predictors of voriconazole concentrations, and univariable logistic regression analysis, to study the relationship between voriconazole concentrations and adverse effects. During the 2-year study period, 70 patients were included. Optimal trough voriconazole concentrations were reported in 37 patients (52.8%), subtherapeutic in 20 (28.6%), and supratherapeutic in 13 (18.6%). Adverse effects were reported in six (8.6%) patients. SOFA score was identified as a factor associated with an increase in voriconazole concentration (p = 0.025), mainly in the group of patients who had SOFA score \u2265 10. Moreover, an increase in voriconazole concentration was shown to be a risk factor for occurrence of adverse effects (p = 0.011). In that respect, critically ill patients who received voriconazole treatment must benefit from a TDM, particularly if they have a SOFA score \u2265 10. Indeed, identifying patients who are overdosed will help to prevent voriconazole related adverse effects. This result is of utmost importance given the recognized COVID-19-associated pulmonary aspergillosis in ICU patients for whom voriconazole is among the recommended first-line treatment.<\/jats:p>","DOI":"10.1371\/journal.pone.0260656","type":"journal-article","created":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T18:28:46Z","timestamp":1637778526000},"page":"e0260656","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":12,"title":["Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1502-1851","authenticated-orcid":true,"given":"Anne-Lise","family":"Bienvenu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Pradat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Plesa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Piriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Luc","family":"Fellahi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Argaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Rimmel\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean","family":"Menotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Aubrun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Christophe","family":"Richard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-Claude","family":"Gagnieu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Parant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Chidiac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7043-9834","authenticated-orcid":true,"given":"Gilles","family":"Leboucher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michel","family":"Tod","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvain","family":"Goutelle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2021,11,24]]},"reference":[{"key":"pone.0260656.ref001","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00134-017-4731-2","article-title":"Intensive care medicine research agenda on invasive fungal infection in critically ill patients","volume":"43","author":"M Bassetti","year":"2017","journal-title":"Intensive Care Medicine"},{"key":"pone.0260656.ref002","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1093\/jac\/dkw099","article-title":"Utility of voriconazole therapeutic drug monitoring: a meta-analysis","volume":"71","author":"M-L Luong","year":"2016","journal-title":"Journal of Antimicrobial Chemotherapy"},{"key":"pone.0260656.ref003","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1592\/phco.31.2.214","article-title":"Therapeutic Drug Monitoring of Voriconazole and Posaconazole","volume":"31","author":"T Hussaini","year":"2011","journal-title":"Pharmacotherapy"},{"key":"pone.0260656.ref004","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ijantimicag.2009.12.021","article-title":"Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.","volume":"35","author":"P Myrianthefs","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0260656.ref005","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01245-19","article-title":"Impact of Triazole Therapeutic Drug Monitoring Availability and Timing","volume":"63","author":"EK McCreary","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0260656.ref006","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40121-020-00280-y","article-title":"Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?","volume":"9","author":"A Vena","year":"2020","journal-title":"Infect Dis Ther."},{"key":"pone.0260656.ref007","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/jcpt.12817","article-title":"Impact of voriconazole plasma concentrations on treatment response in critically ill patients","volume":"44","author":"J Ruiz","year":"2019","journal-title":"J Clin Pharm Ther"},{"key":"pone.0260656.ref008","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1002\/phar.1779","article-title":"Risk Factors for Voriconazole-Associated Hepatotoxicity in Patients in the Intensive Care Unit","volume":"36","author":"Y Wang","year":"2016","journal-title":"Pharmacotherapy"},{"key":"pone.0260656.ref009","article-title":"Voriconazole therapeutic drug monitoring in critically ill patients improves efficacy and safety of antifungal therapy","author":"H Li","year":"2020","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"pone.0260656.ref010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America","volume":"63","author":"TF Patterson","year":"2016","journal-title":"Clinical Infectious Diseases"},{"key":"pone.0260656.ref011","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00134-020-06050-1","article-title":"Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper#.","volume":"46","author":"the Infection Section of European Society of Intensive Care Medicine (ESICM)","year":"2020","journal-title":"Intensive Care Medicine"},{"key":"pone.0260656.ref012","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/cid\/cis599","article-title":"The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial","volume":"55","author":"WB Park","year":"2012","journal-title":"Clinical Infectious Diseases"},{"key":"pone.0260656.ref013","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.1093\/infdis\/jiaa394","article-title":"Core Recommendations for Antifungal Stewardship: A Statement of the Mycoses Study Group Education and Research Consortium","volume":"222","author":"MD Johnson","year":"2020","journal-title":"The Journal of Infectious Diseases"},{"key":"pone.0260656.ref014","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance","volume":"21","author":"P Koehler","year":"2021","journal-title":"Lancet Infect Dis."},{"key":"pone.0260656.ref015","doi-asserted-by":"crossref","first-page":"e0238825","DOI":"10.1371\/journal.pone.0238825","article-title":"Invasive pulmonary aspergillosis in critically ill patients with severe COVID-19 pneumonia: Results from the prospective AspCOVID-19 study","volume":"16","author":"T Lahmer","year":"2021","journal-title":"PLoS ONE"},{"key":"pone.0260656.ref016","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nrgastro.2016.168","article-title":"Liver\u2014guardian, modifier and target of sepsis","volume":"14","author":"P Strnad","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"pone.0260656.ref017","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1093\/jac\/dkw045","article-title":"Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis","volume":"71","author":"H Jin","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"pone.0260656.ref018","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1111\/myc.13129","article-title":"Effects of antifungal stewardship using therapeutic drug monitoring in voriconazole therapy on the prevention and control of hepatotoxicity and visual symptoms: A multicentre study conducted in Japan","volume":"63","author":"Y Hamada","year":"2020","journal-title":"Mycoses."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260656","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T18:29:03Z","timestamp":1637778543000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0260656"}},"subtitle":[],"editor":[{"given":"Tai-Heng","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2021,11,24]]},"references-count":18,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,11,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0260656","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,24]]}}}